Pediatrics

Principles of Fluid Calculation in Extreme Preterm Neonates

Extremely preterm infants have markedly elevated insensible water losses from immature, thin skin (poorly keratinized stratum corneum), a very high surface area-to-body-weight ratio, and additional evaporative losses from radiant warmers/phototherapy.

• Typical Day 1 starting fluids for extreme preterm infants: ~60–80 mL/kg/day (vs ~60 mL/kg/day for term infants), with humidified incubator environments used to reduce insensible losses
• Fluids increased incrementally (~10–20 mL/kg/day), guided by daily weight, serum electrolyte trends, and urine output rather than a rigid fixed schedule

Physiological Weight Loss

Both term and preterm infants normally lose weight in the first several days, reflecting postnatal contraction of the extracellular fluid compartment. Typical loss is ~5–10% of birth weight in term infants, up to ~10–15% in preterm infants. Birth weight is typically regained by 7–10 days (term). Excessive loss suggests inadequate fluid/dehydration; failure to lose any weight suggests fluid overload — both warrant fluid plan review.

Management of Hyperkalemia

Characteristic in extreme preterm infants during the first 24–72 hours as “non-oliguric hyperkalemia of prematurity” — immature renal tubular potassium handling plus an intracellular-to-extracellular potassium shift, occurring independently of oliguria/renal dysfunction.

• Avoidance/minimization of exogenous potassium until resolved and urine output established
• IV calcium gluconate — cardioprotective, membrane-stabilizing (does not lower potassium itself)
• Insulin-dextrose infusion and nebulized salbutamol — drive potassium intracellularly, temporary effect
• Potassium-binding resins, or dialysis (peritoneal) for severe/refractory cases

Management of Hypernatremia

Typically reflects excessive free water loss rather than sodium excess. Management centers on increasing free water provision rather than sodium restriction. Gradual, controlled correction is essential given cerebral edema risk with overly rapid correction — target no faster than ~0.5 mEq/L per hour, ~10–12 mEq/L reduction over 24 hours.

Pathophysiology

Vitamin K is an essential cofactor for hepatic gamma-carboxylation of clotting factors II, VII, IX, X (and proteins C and S). Neonates are physiologically vitamin K deficient at birth due to poor placental transfer, low hepatic stores, and (postnatally) minimal breast milk content plus a sterile, immature gut microbiome unable to synthesize vitamin K endogenously.

Three Temporal Patterns of VKDB

Clinical Features

Bleeding from relevant sites depending on temporal pattern; intracranial hemorrhage presents with irritability, poor feeding, bulging fontanelle, seizures, or rapid deterioration — a genuine neonatal emergency.

Prophylactic Regimens

• Universal administration of Vitamin K (Phytomenadione, K1) to every newborn at birth, without exception
• Intramuscular (single dose, typically 1 mg for term infants, weight-adjusted for preterm) is preferred — superior, more sustained protection across all three patterns compared to oral
• Oral vitamin K — alternative when IM is refused/unavailable, requiring a multi-dose regimen (birth, ~1 week, ~4–6 weeks); higher risk of prophylaxis failure, particularly for late VKDB, if doses are missed

Universal vitamin K prophylaxis has been associated with a dramatic, well-documented reduction in VKDB incidence globally and is a standard, non-negotiable component of routine newborn care.

Aetiology of Congenital Hydrocephalus

Obstructive (non-communicating): CSF flow mechanically blocked — aqueductal stenosis, Chiari II malformation (associated with myelomeningocele), Dandy-Walker malformation, congenital intracranial tumors.

Communicating: CSF flow unobstructed but reabsorption impaired (arachnoid granulations) — post-hemorrhagic hydrocephalus (following IVH), post-infectious hydrocephalus (toxoplasmosis, CMV, meningitis).

Genetic causes: X-linked hydrocephalus (L1CAM gene mutations), particularly with a positive family history or adducted thumbs.

Antenatal Screening

Routine antenatal ultrasound is primary screening, with ventriculomegaly defined by lateral ventricular atrial diameter >10 mm. Fetal MRI is increasingly used to characterize associated structural anomalies for prognostic counseling and delivery planning.

Surgical Options — ETV versus VP Shunt

The ETV Success Score (incorporating age, etiology, prior shunt history) predicts likely success. ETV combined with Choroid Plexus Cauterization (ETV+CPC) has demonstrated improved success, particularly in infants and post-infectious hydrocephalus, extensively validated in resource-limited settings (notably East Africa).

Prevention of Neural Tube Defects with Folic Acid

• Standard-risk women: 0.4 mg (400 mcg) daily, initiated at least one month before conception and continued through at least the first trimester — periconceptional timing is critical since neural tube closure completes by ~day 28 of gestation, often before pregnancy is confirmed
• Higher-risk women (prior NTD-affected pregnancy, certain anticonvulsants, pre-existing diabetes): 4–5 mg daily
• Mandatory food fortification programs (e.g., flour fortification) have demonstrated clear population-level reductions in NTD incidence

Fetal Circulation — Key Features (Background)

In the fetal state, the lungs are fluid-filled and functionally inactive for gas exchange; oxygenation occurs entirely via the placenta. Pulmonary vascular resistance (PVR) is physiologically high while systemic (placental) resistance is low, driving blood away from the lungs and toward the placenta via three key shunts:

• Ductus venosus — shunts oxygenated umbilical venous blood, largely bypassing hepatic sinusoidal circulation, into the IVC
• Foramen ovale — a flap-valve shunting well-oxygenated IVC blood from the right atrium to the left atrium, bypassing the lungs
• Ductus arteriosus — shunts blood from the main pulmonary artery directly into the descending aorta, bypassing the pulmonary circulation

The Sequence of Cardiovascular and Pulmonary Adaptation at Birth

1. Lung expansion and onset of breathing — mechanical expansion and rising oxygen tension trigger pulmonary vasodilation, mediated by nitric oxide/prostacyclin and withdrawal of hypoxic pulmonary vasoconstriction
2. Dramatic fall in Pulmonary Vascular Resistance (PVR) — the central hemodynamic event; pulmonary blood flow increases ~8- to 10-fold vs fetal baseline
3. Clamping of the umbilical cord — removal of the low-resistance placental bed raises systemic vascular resistance (SVR), the mirror-image of falling PVR
4. Reversal of the pressure gradient across the foramen ovale — rising pulmonary venous return and rising SVR cause left atrial pressure to exceed right atrial pressure, functionally closing the flap valve (true anatomical closure occurs over subsequent weeks/months; ~25% remain probe-patent, generally without clinical consequence)
5. Closure of the ductus arteriosus — rising arterial oxygen tension triggers active constriction of the uniquely oxygen-sensitive ductal smooth muscle (contrasting with pulmonary vasculature's vasodilatory response); falling circulating prostaglandin E2 (placental source lost with cord clamping) also contributes. Functional closure typically within 24–48 hours, anatomical closure (fibrosis) over subsequent weeks, forming the ligamentum arteriosum
6. Closure of the ductus venosus — passive closure over ensuing days following cessation of umbilical venous flow, forming the ligamentum venosum

Clinical Relevance and Cross-Links

This transition sequence directly underpins: PPHN (failure of the normal postnatal PVR fall — see Q7), the time-course of ductal-dependent congenital heart lesions (asymptomatic in utero/immediately after birth, decompensating as the ductus closes over 24–48 hours — explaining the classic day 2–3 collapse), and the rationale for prostaglandin E1 infusion, which exploits the ductus's oxygen/prostaglandin sensitivity to pharmacologically maintain patency in ductal-dependent lesions pending definitive management.

Rationale for a Pediatric-Specific Definition

PARDS requires its own definitional framework rather than downward extrapolation of the adult Berlin ARDS criteria, because pediatric critical care commonly employs non-invasive respiratory support (HFNC, NIV) and monitoring approaches (frequent use of SpO₂/FiO₂ ratios rather than PaO₂/FiO₂, given the rarity of arterial line placement in non-invasively supported children) that the adult framework does not accommodate. The original PALICC (2015) was updated to PALICC-2 in 2023.

PALICC-2 Definitional Framework — Key Elements

• Timing: onset within 7 days of a known clinical insult
• Origin of edema: respiratory failure not fully explained by cardiac failure or fluid overload alone
• Chest imaging: new infiltrate(s) consistent with acute pulmonary parenchymal disease (a refinement from strict Berlin-style bilateral infiltrate requirements, given inter-observer variability in pediatric imaging)

Oxygenation criteria, stratified by respiratory support modality:

• For invasively ventilated patients: Oxygenation Index (OI) or Oxygenation Saturation Index (OSI, using SpO₂) thresholds define mild/moderate/severe PARDS
• For non-invasively supported patients (CPAP/BiPAP at a minimum pressure threshold, or in some circumstances HFNC at sufficient flow): PaO₂/FiO₂ ≤300 or SpO₂/FiO₂ ≤264 defines “at-risk” or mild PARDS, allowing earlier recognition before invasive ventilation
• Explicit accommodation for cyanotic congenital heart disease and chronic lung disease patients, given altered baseline physiology

Mechanical Ventilation Strategies

• Low tidal volumes, generally 5–8 mL/kg predicted body weight (closer to 5–6 mL/kg with poorer compliance)
• Limiting plateau pressure, generally ≤28–32 cmH₂O (higher end acceptable with reduced chest wall compliance)
• Adequate PEEP titration balancing recruitment against over-distension
• Permissive hypercapnia, used cautiously/avoided with significant intracranial hypertension or pulmonary hypertension

HFOV may be considered as a rescue strategy for severe PARDS refractory to optimized conventional ventilation, though its role has become more selective given mixed evidence. Prone positioning is recommended as an adjunct for severe PARDS (informed by adult PROSEVA trial evidence with growing pediatric data), requiring careful protocol-driven implementation.

Additional Adjunctive Therapies

Neuromuscular blockade for severe PARDS with significant patient-ventilator dyssynchrony not controlled by sedation alone (used judiciously given ICU-acquired weakness risk). Conservative, restrictive fluid management once initial resuscitation is complete. Early, adequately dosed enteral nutrition where feasible.

ECMO Indications

Considered for severe PARDS refractory to optimized conventional and rescue strategies (including HFOV and prone positioning where attempted), guided by persistently severe oxygenation indices — reflecting a judgment that ongoing high-intensity mechanical ventilation is itself causing more harm than benefit, and that extracorporeal support allows lung recovery while avoiding further iatrogenic injury.

Definitions

• T1 (time point at which treatment should be initiated): a single seizure lasting ≥5 minutes, or recurrent seizures without full recovery of consciousness between episodes
• T2 (time point beyond which long-term consequences — neuronal injury, network reorganization favoring further seizures — become increasingly likely): ~30 minutes for convulsive SE (shorter, ~10–15 minutes for absence status; longer, ~60 minutes for focal status with impaired awareness)

This T2 concept underscores why status epilepticus management is explicitly time-driven rather than escalating therapy at arbitrary intervals.

Time-Anchored Management Protocol

0–5 minutes (Stabilization): ABC assessment, oxygen, IV/IO access, point-of-care glucose (immediate correction of hypoglycemia if present), baseline investigations (electrolytes, calcium, magnesium, anticonvulsant levels, toxicology screen where indicated).

5–20 minutes (First-line — Benzodiazepines):

• IV Lorazepam (0.1 mg/kg, max 4 mg per dose) — preferred first-line where IV access is available
• IV Diazepam (0.2–0.3 mg/kg) — alternative
• Non-IV routes where IV access not yet established: Buccal/Intranasal Midazolam (0.2–0.3 mg/kg) or Rectal Diazepam (0.5 mg/kg) — particularly emphasized for pre-hospital/first-responder settings
• A second benzodiazepine dose may be given if seizure persists 5 minutes after the first dose; repeated dosing beyond this should prompt escalation to second-line therapy rather than further repetition

20–40 minutes (Second-line — IV Antiseizure Medications): the ESETT trial demonstrated Levetiracetam, Fosphenytoin, and Valproate are broadly comparably effective (~45–50% seizure termination with any of the three), superseding older teaching favoring phenytoin/fosphenytoin as the default choice.

40–60 minutes and beyond (Refractory Status Epilepticus): continuous infusion anesthetic-dose therapy, typically requiring intubation, mechanical ventilation, and continuous EEG monitoring (electrographic seizures may persist despite cessation of visible convulsive activity — “subtle”/non-convulsive status):

• Midazolam infusion
• Pentobarbital infusion
• Propofol infusion (caution — Propofol Infusion Syndrome risk with prolonged, high-dose use in children)

Continued seizure activity despite these measures constitutes super-refractory status epilepticus, requiring specialized management (ketamine infusion, ketogenic diet initiation, immunotherapy if autoimmune/inflammatory etiology suspected, and in select cases surgical evaluation).

Etiological Evaluation

Parallel to treatment: febrile status epilepticus (most common in young children), CNS infection (meningitis, encephalitis — low threshold for empirical coverage and LP once stable), metabolic derangement (hypoglycemia, hyponatremia, hypocalcemia), structural lesion (neuroimaging for focal-onset seizures/deficits), toxic ingestion, known epilepsy with breakthrough seizures (often sub-therapeutic levels), and autoimmune/inflammatory encephalitis (particularly in refractory/super-refractory cases).

Diagnostic Criteria

DKA is biochemically defined by the triad of hyperglycemia (blood glucose typically >200 mg/dL, though can occasionally be lower — “euglycemic DKA”), metabolic acidosis (venous pH <7.3 or bicarbonate <15 mmol/L), and ketosis (ketonemia and/or ketonuria).

Severity Classification

Management Protocol

1. Initial assessment and fluid deficit estimation: dehydration typically estimated at 5–10%, though clinical assessment is notoriously unreliable in DKA given hyperosmolality maintains intravascular volume better than expected. Fluid deficit is replaced gradually over 24–48 hours, not rapidly
2. Initial fluid bolus: a modest 10 mL/kg of 0.9% saline over 1–2 hours, primarily to restore perfusion in a shocked/significantly dehydrated child — deliberately more conservative than boluses used in other forms of shock
3. Ongoing fluid replacement: calculated deficit plus maintenance replaced evenly over 24–48 hours, using 0.9% saline initially, with sodium content adjusted based on corrected sodium trend
4. Insulin therapy: continuous IV regular insulin infusion, 0.05–0.1 units/kg/hour, started only after the initial fluid bolus (typically 1–2 hours after fluid initiation, not simultaneously). No initial insulin bolus in current pediatric protocols
5. Potassium replacement: essential and started early (once initial potassium and urine output are confirmed adequate) — total body potassium is significantly depleted despite normal/elevated serum levels at presentation (transcellular shift from acidosis/insulin deficiency); without proactive replacement, life-threatening hypokalemia develops as treatment proceeds
6. Monitoring: hourly (or more frequent) neurological status assessment, hourly vitals, glucose monitoring; electrolytes (including corrected sodium) and venous blood gas rechecked every 2–4 hours
7. Transition to subcutaneous insulin: once acidosis resolved (pH >7.3, bicarbonate >15) and tolerating oral intake, with IV infusion overlapped 30–60 minutes after the first SC dose

Pathophysiology, Prevention, and Treatment of DKA-Related Cerebral Edema

Pathophysiology: occurs in ~0.5–1% of pediatric DKA episodes but accounts for a disproportionate share of DKA-related mortality/morbidity. Contemporary understanding recognizes cerebral hypoperfusion and vasogenic injury during the DKA episode itself (before treatment begins) as an important contributing factor — not solely an iatrogenic consequence of treatment. Risk factors: younger age, new-onset diabetes, more severe acidosis, higher initial BUN, failure of corrected serum sodium to rise appropriately as glucose falls. The PECARN FLUID trial found no significant difference in neurological outcomes between rapid vs slow fluid replacement — a nuanced, actively debated point.

Prevention: avoid excessive fluid/repeated boluses beyond the initial modest bolus; gradual deficit replacement over 24–48 hours; avoid early aggressive insulin bolusing; monitor corrected sodium trend closely; frequent structured neurological status assessment throughout treatment.

Clinical recognition: headache, recurrence of vomiting after initial improvement, irritability/increasing lethargy, specific neurological signs (cranial nerve palsies, pupillary changes), rising blood pressure with falling heart rate (Cushing's-triad-like), declining oxygen saturation — any of these should prompt immediate treatment without waiting for imaging.

Treatment (a genuine medical emergency once suspected): immediate reduction of IV fluid rate to the minimum required; hyperosmolar therapy — Mannitol (0.5–1 g/kg IV) or hypertonic (3%) saline (5–10 mL/kg), given promptly without waiting for imaging; head elevation and general neuroprotective measures; urgent CT head once emergency treatment has been given; involvement of pediatric critical care/neurology.

Initial Assessment and Severity Stratification

Assessed via respiratory rate, accessory muscle use, ability to speak in full sentences, oxygen saturation, and degree of air entry/wheeze. A “silent chest” (essentially no air movement to generate audible wheeze) is a critical, ominous sign of impending respiratory failure — not a reassuring absence of pathology, and a frequently-tested “trick” exam point.

Stepwise Pharmacological Management

• First-line — Inhaled SABA (Salbutamol/Albuterol): via nebulization or, increasingly preferred, MDI with spacer (comparable/superior efficacy, reduced aerosol generation); given as repeated doses/continuous nebulization in severe presentations
• Ipratropium bromide added to beta-agonist therapy for moderate-severe exacerbations — additive bronchodilator benefit and reduced hospitalization when combined early, though less clear benefit once already admitted
• Systemic corticosteroids (oral or IV) given early in any moderate-severe exacerbation — central role in resolving airway inflammation, onset of benefit within several hours
• IV Magnesium Sulfate for severe exacerbations not responding to initial bronchodilator/steroid therapy — bronchial smooth muscle relaxant via calcium channel modulation, reduces hospital admission
• IV Aminophylline/Theophylline — older-generation escalation option for severe refractory exacerbations, progressively less common given narrow therapeutic index and level monitoring requirement
• Continuous nebulized/IV salbutamol infusion — for the most severe, refractory cases, under close monitoring for cardiac/electrolyte effects (tachycardia, hypokalemia)

Mechanical Ventilation Considerations

Intubation is approached with particular caution, reserved for genuine impending respiratory failure (progressive exhaustion, worsening hypercapnia with acidosis, declining mental status, or cardiorespiratory arrest), given risks of positive-pressure ventilation with severe airflow obstruction — specifically dynamic hyperinflation (“breath-stacking”) and consequent barotrauma or reduced venous return/cardiac output. When intubation is necessary: relatively low respiratory rates and prolonged expiratory time, acceptance of permissive hypercapnia, and vigilant monitoring for auto-PEEP/dynamic hyperinflation, with a low threshold to briefly disconnect the circuit if acute hemodynamic deterioration suggests severe breath-stacking.

Clinical Diagnostic Criteria

Anaphylaxis is diagnosed clinically when any ONE of the following is met, and does not require laboratory confirmation for immediate treatment decisions:

1. Acute onset (minutes to hours) involving skin/mucosal tissue (hives, itching, flushing, swollen lips/tongue/uvula) PLUS at least one of: respiratory compromise (dyspnea, wheeze/bronchospasm, stridor, reduced peak flow, hypoxemia) OR reduced blood pressure/end-organ dysfunction (hypotonia, syncope, incontinence)
2. Two or more of the following occurring rapidly after exposure to a likely allergen: skin/mucosal involvement, respiratory compromise, reduced blood pressure/associated symptoms, or persistent GI symptoms (crampy abdominal pain, vomiting)
3. Reduced blood pressure after exposure to a KNOWN allergen for that patient (even without typical skin/respiratory features) — important for recognizing atypical presentations, since a minority of cases lack prominent cutaneous findings

Immediate Management

Intramuscular Epinephrine — the immediate, first-line, life-saving treatment, with no substitute or acceptable delay:

• Dose: 0.01 mg/kg of 1:1000 concentration (max single dose 0.3–0.5 mg), IM into the anterolateral thigh (vastus lateralis) — more rapid, reliable absorption vs subcutaneous or deltoid IM injection
• May be repeated every 5–15 minutes if inadequate response
• Delay (attempting antihistamines/steroids first, or hesitating due to diagnostic uncertainty) is a well-recognized, preventable contributor to fatal outcomes — epinephrine should never be delayed or omitted in favor of “safer-seeming” adjuncts

Airway/cardiovascular stabilization proceeds simultaneously: high-flow oxygen, positioning (supine with legs elevated if hypotensive, upright if respiratory distress predominates), large-bore IV access, and fluid bolus for hypotension not responding to initial epinephrine.

Adjunct Medications

Antihistamines (H1 blockers ± H2 blockers) relieve cutaneous symptoms but do not address respiratory/cardiovascular components and must never substitute for epinephrine. Systemic corticosteroids are commonly given, though evidence for reducing biphasic reaction risk has been increasingly questioned. Nebulized bronchodilators are added for significant bronchospasm as an adjunct, not replacement.

Biphasic Reaction Monitoring

A recognized proportion of episodes recur (biphasic reaction), typically within 1–72 hours (most commonly first 8–10 hours) after apparent resolution, without further allergen re-exposure. Patients require observation (commonly 4–6 hours for milder reactions, longer/overnight for severe presentations, multiple epinephrine doses, or significant respiratory involvement) before discharge, along with a self-injectable epinephrine auto-injector prescription, allergen avoidance counseling, and formal allergy evaluation referral.

Monro-Kellie Doctrine

The skull is a rigid, fixed-volume compartment containing brain parenchyma, blood, and CSF, such that an increase in the volume of any one component must be compensated by a proportionate decrease in one or both of the others, or ICP will rise. Initially, compensatory mechanisms (CSF displacement into the spinal canal, venous blood volume reduction) accommodate modest volume increases with minimal ICP rise; once this reserve is exhausted, further small increases produce disproportionately steep ICP rises — explaining sudden clinical deterioration after a period of apparent relative stability.

Clinical Signs of Raised ICP and Herniation Syndromes

Early/non-specific: headache, vomiting (classically early-morning), irritability, lethargy; in infants, bulging anterior fontanelle and increasing head circumference. More specific/concerning: Cushing's triad (hypertension, bradycardia, irregular respiration — a late, ominous finding reflecting brainstem compression, not primary hypertension to be treated in isolation), papilledema, and specific herniation patterns (uncal/transtentorial — fixed dilated pupil with contralateral hemiparesis; tonsillar — risk of sudden cardiorespiratory arrest from medullary compression).

Medical Management

• Head elevation to 30 degrees with neck in neutral position, avoiding rotation/flexion impairing jugular venous drainage
• Adequate sedation/analgesia to prevent agitation, coughing, straining-related ICP surges; neuromuscular blockade added in refractory cases
• Hyperosmolar therapy: Hypertonic saline (3%) — increasingly favored first-line, effective while maintaining/supporting intravascular volume/BP; Mannitol — effective alternative/adjunct, but its diuretic effect requires careful volume status attention
• Controlled, brief hyperventilation (low-normal to mildly reduced PaCO₂) for acute severe ICP elevation/impending herniation as a temporizing measure only — prolonged/aggressive hyperventilation avoided given cerebral vasoconstriction/secondary ischemia risk
• Maintenance of adequate cerebral perfusion pressure (CPP = MAP − ICP) — avoiding and promptly correcting systemic hypotension
• Temperature control — actively avoiding/treating hyperthermia
• CSF drainage via external ventricular drain where hydrocephalus/CSF-related pressure elevation contributes
• Surgical decompression (decompressive craniectomy) reserved for raised ICP refractory to maximal medical management, particularly large territory injury causing malignant edema
• Invasive ICP monitoring (typically severe TBI with abnormal CT and depressed GCS) to guide targeted management toward a defined threshold (generally <20 mmHg, age-adjusted) and adequate CPP